Theravance Biopharma (NASDAQ:TBPH) Price Target Cut to $21.00 by Analysts at BTIG Research

Theravance Biopharma (NASDAQ:TBPH) had its target price decreased by BTIG Research from $40.00 to $21.00 in a research note released on Tuesday morning, Marketbeat.com reports. BTIG Research currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on TBPH. HC Wainwright upped their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday. Wall Street Zen cut shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Oppenheimer started coverage on shares of Theravance Biopharma in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 target price for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $25.40.

Theravance Biopharma Stock Down 26.3%

Shares of Theravance Biopharma stock opened at $13.96 on Tuesday. The stock has a market cap of $707.35 million, a P/E ratio of 24.49 and a beta of 0.17. Theravance Biopharma has a 12-month low of $7.90 and a 12-month high of $21.03. The business’s 50 day moving average is $19.26 and its 200-day moving average is $16.88.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new stake in shares of Theravance Biopharma during the first quarter worth approximately $101,000. Jane Street Group LLC lifted its holdings in Theravance Biopharma by 169.2% during the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after purchasing an additional 88,540 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Theravance Biopharma in the 2nd quarter valued at $452,000. Los Angeles Capital Management LLC acquired a new position in Theravance Biopharma in the 2nd quarter valued at $219,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Theravance Biopharma in the 2nd quarter valued at $624,000. 99.10% of the stock is owned by institutional investors.

Key Theravance Biopharma News

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company reports a strong cash position (about $326.5M at Q4 2025 and ~ $400M expected at end-Q1 2026 including milestones), no debt, and confidence in a $100M 2026 TRELEGY milestone — provides near-term runway. PR Newswire Release
• Positive Sentiment: Board announced accelerated strategic review and a restructuring expected to cut the cost base by ~60% (~$70M), targeting $60–70M of annualized cash flow; company is narrowing to a portfolio focused on YUPELRI, which generated durable revenues (FY2025 net sales recognized by Viatris $266.6M, +12% YoY). PR Newswire Release
• Neutral Sentiment: Analyst actions are mixed but still show some institutional support: BTIG cut its price target to $21 but kept a Buy rating, while HC Wainwright recently raised its target to $27 — signals divergent views on post-trial valuation. BTIG / StreetInsider HC Wainwright note
• Negative Sentiment: Topline from the Phase 3 CYPRESS study: ampreloxetine did not meet the primary endpoint (OHSA composite score) in patients with neurogenic orthostatic hypotension due to MSA — the clinical failure removes the lead late‑stage opportunity. Benzinga: Trial Miss
• Negative Sentiment: Management said it is accelerating a strategic review that could include a sale; media report the company is working with advisors (Lazard) — this signals material uncertainty about TBPH’s standalone future and likely near-term volatility. Reuters: Strategic Review
• Negative Sentiment: Market response: shares plunged and trading was briefly halted; unusually large put-option activity suggests elevated short-term bearish positioning and higher volatility. Proactive Investors: Market Reaction

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.